Biolase Announces Management Change

IRVINE, Calif.--()--BIOLASE, Inc. (NASDAQ:BIOL), the world’s leading manufacturer and distributor of dental lasers, today reported that Alexander K. Arrow, M.D. has resigned as Chief Medical Officer and will be leaving the Company effective December 3, 2014 to pursue other opportunities.

Jeffrey M. Nugent, President and Chief Executive Officer, stated, “Alex is a consummate team player who has changed roles several times at BIOLASE -- each time in response to what needed to be done. While at the Company, Alex stood up for what was best for BIOLASE, its customers, and its shareholders while it was undergoing a Board transition this spring. We appreciate his untiring efforts during his tenure and we wish him the best in the next phase of his career.”

Dr. Arrow joined the BIOLASE Board of Directors in July 2010. He remained on the Board and served as chairman of the Audit and Compensation committees until June 2013. In June 2013, he was named President and Chief Operating Officer and he served in that role until he was appointed Chief Medical Officer in September of this year.

Dr. Arrow commented, “I’m pleased to have played a role in the reshaping of the Company and to have helped develop its new strategy. Now it is time to execute that strategy under the leadership of President and Chief Executive Officer Jeff Nugent. I’m also proud that the people I recruited to BIOLASE are in senior leadership positions that make use of their talents. I wish the Company well and appreciate having had the opportunity to serve its stakeholders.”

About BIOLASE, Inc.

BIOLASE, Inc. is a biomedical device company that develops, manufactures, and markets innovative lasers in dentistry and medicine and also markets and distributes high-end 2D and 3D digital imaging equipment, CAD/CAM intraoral scanners, and in-office milling machines and 3D printers. BIOLASE’s products are focused on technologies that advance the practice of dentistry and medicine and offer benefits and value to healthcare professionals and their patients. The Company's proprietary laser products incorporate approximately 250 patented and patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold approximately 26,800 laser systems. Laser products under development address the Company’s core dental market and other adjacent medical and consumer markets.

For updates and information on WaterLase and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Pinterest at www.pinterest.com/biolase, LinkedIn at www.linkedin.com/company/biolase, Google+ at www.google.com/+BIOLASEIrvine, Instagram at www.instagram.com/biolaseinc, and YouTube at www.youtube.com/biolasevideos.

BIOLASE® and WaterLase® are registered trademarks of BIOLASE, Inc.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Statements contained in this press release that refer to BIOLASE's estimated or anticipated future results or other non-historical facts are forward-looking statements, as are any statements in this press release concerning prospects related to BIOLASE's strategic initiatives and anticipated financial performance. Forward-looking statements can also be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations regarding existing trends, our strategic initiatives, the closing of the private placement and expected use of proceeds and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors affecting BIOLASE’s business. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that may be detailed, from time-to-time, in BIOLASE's reports filed with the SEC. BIOLASE does not undertake any responsibility to revise or update any forward-looking statements contained herein.

Contacts

Allen & Caron
Rene Caron
949-474-4300
rene@allencaron.com
or
Len Hall (Media)
949-474-4300
len@allencaron.com

Contacts

Allen & Caron
Rene Caron
949-474-4300
rene@allencaron.com
or
Len Hall (Media)
949-474-4300
len@allencaron.com